Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
Portfolio Pulse from
Viking Therapeutics will present Phase 2b trial results of VK2809 for NASH/MASH at the 75th Liver Meeting 2024. The data will be featured in an oral late breaker presentation, highlighting the potential of VK2809 as a novel treatment for liver diseases.
November 12, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viking Therapeutics will present promising Phase 2b trial results of VK2809 for NASH/MASH at a major liver disease conference, potentially boosting investor confidence and impacting stock prices.
The presentation of Phase 2b trial results at a major conference suggests significant progress in VK2809's development, which could lead to increased investor interest and a positive impact on Viking Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100